Sigma Planning Corp’s Ligand Pharmaceuticals LGND Stock Holding History

Sigma Planning Corp’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,500	Closed	-$898K	–	1450
2026 Q1	$898K	Buy	4,500 +1,500	+50%	+$297K	0.03%	606
2025 Q4	$567K	Buy	+3,000	New	+$576K	0.02%	746
2019 Q2	–	Sell	-2,970	Closed	-$233K	–	1026
2019 Q1	$233K	Buy	+2,970	New	+$225K	0.01%	781
2018 Q4	–	Sell	-2,106	Closed	-$361K	–	915
2018 Q3	$361K	Buy	+2,106	New	+$318K	0.02%	611

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sigma Planning Corp's LGND Position: Q2 2026 in Review

Sigma Planning Corp sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 4,500 shares — an estimated $898K sold.

Sigma Planning Corp first reported a position in LGND in Q3 2018 and held it in 4 quarters. The position peaked at $898K in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Sigma Planning Corp reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sigma Planning Corp sold 4,500 Ligand Pharmaceuticals shares in Q2 2026, an estimated $898K.
Sigma Planning Corp first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Sigma Planning Corp's Ligand Pharmaceuticals position peaked at $898K in Q1 2026.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.